These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 27411865)

  • 1. Multiple myeloma--translation of trial results into reality.
    Moreau P; Rajkumar SV
    Lancet; 2016 Jul; 388(10040):111-3. PubMed ID: 27411865
    [No Abstract]   [Full Text] [Related]  

  • 2. [Molecular targeting agents for multiple myeloma].
    Fujii S; Abe M
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():518-23. PubMed ID: 23513894
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapy sequencing strategies in multiple myeloma: who, what and why?
    Costello C; Mikhael JR
    Future Oncol; 2018 Jan; 14(2):95-99. PubMed ID: 29219615
    [No Abstract]   [Full Text] [Related]  

  • 4. Drugs: More shots on target.
    Appel A
    Nature; 2011 Dec; 480(7377):S40-2. PubMed ID: 22169800
    [No Abstract]   [Full Text] [Related]  

  • 5. Proteasome inhibitors for the treatment of multiple myeloma.
    Scalzulli E; Grammatico S; Vozella F; Petrucci MT
    Expert Opin Pharmacother; 2018 Mar; 19(4):375-386. PubMed ID: 29478351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current status of clinical trials of novel agents for multiple myeloma].
    Kuroda J
    Rinsho Ketsueki; 2014 Oct; 55(10):2005-15. PubMed ID: 25297766
    [No Abstract]   [Full Text] [Related]  

  • 7. Three new drugs for multiple myeloma.
    Med Lett Drugs Ther; 2016 May; 58(1495):e70-1. PubMed ID: 27192621
    [No Abstract]   [Full Text] [Related]  

  • 8. Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.
    Moreau P; de Wit E
    Br J Haematol; 2017 Oct; 179(2):198-218. PubMed ID: 28556890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome Inhibitors as a Potential Cause of Heart Failure.
    Koulaouzidis G; Lyon AR
    Heart Fail Clin; 2017 Apr; 13(2):289-295. PubMed ID: 28279415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of novel therapies in high-molecular-risk multiple myeloma.
    Lancman G; Tremblay D; Barley K; Barlogie B; Cho HJ; Jagannath S; Madduri D; Moshier E; Parekh S; Chari A
    Clin Adv Hematol Oncol; 2017 Nov; 15(11):870-879. PubMed ID: 29200420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future.
    Diamond B; Maclachlan K; Chung DJ; Lesokhin AM; Ola Landgren C
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101140. PubMed ID: 32139006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New approaches to management of multiple myeloma.
    Genadieva-Stavric S; Cavallo F; Palumbo A
    Curr Treat Options Oncol; 2014 Jun; 15(2):157-70. PubMed ID: 24578203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on ixazomib: potential in the treatment of multiple myeloma.
    Muz B; Ghazarian RN; Ou M; Luderer MJ; Kusdono HD; Azab AK
    Drug Des Devel Ther; 2016; 10():217-26. PubMed ID: 26811670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibitors: structure and function.
    Nunes AT; Annunziata CM
    Semin Oncol; 2017 Dec; 44(6):377-380. PubMed ID: 29935898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of novel proteasome inhibitors in the treatment of relapsed/refractory multiple myeloma].
    Ri M
    Rinsho Ketsueki; 2018; 59(10):2162-2168. PubMed ID: 30305522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel therapies in monoclonal gammopathies.
    Niesvizky R
    Hematology; 2012 Apr; 17 Suppl 1():S121-4. PubMed ID: 22507798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of novel agents for multiple myeloma; now and the future].
    Hata H
    Rinsho Ketsueki; 2011 Aug; 52(8):603-8. PubMed ID: 21897065
    [No Abstract]   [Full Text] [Related]  

  • 18. Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease.
    Sherman DJ; Li J
    Molecules; 2020 Feb; 25(3):. PubMed ID: 32033280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging therapies in multiple myeloma.
    El-Amm J; Tabbara IA
    Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triplet vs. doublet drug regimens for managing multiple myeloma.
    Offidani M; Corvatta L; Gentili S
    Expert Opin Pharmacother; 2018 Feb; 19(2):137-149. PubMed ID: 29265901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.